1
|
Almeida I, Santos H, Santos M, Miranda H, Chin J, Sa C, Almeida S, Sousa C, Almeida L. Antithrombotic strategy in patients with atrial fibrillation and acute coronary syndrome. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Atrial fibrillation (AF) is frequent in patients admitted with acute coronary syndromes (ACS). The development of this arrhythmia occurs in 2–21% of patients with non ST-elevation ACS and 21% of ST-elevation ACS. According with the most recent European guidelines, a short period up to 1 week of triple antithrombotic therapy (TAT) is recommended, followed by dual antithrombotic therapy (DAT) using a NOAC and a single antiplatelet agent, preferably clopidogrel.
Objective
To compare the antithrombotic strategy (DAT vs TAT) used and its prognostic value in patients with AF and ACS.
Methods
Retrospective analysis of patients' data admitted with ACS in a multicentric registry between 10/2010–09/2019. TAT was defined as the prescription of dual antiplatelet therapy and one anticoagulant and DAT as one antiplatelet and one anticoagulant. Survival and rehospitalization were evaluated through Kaplan-Meier curve.
Results
1067 patients were included, mean age 67±14 years, 72.3% male. Patients who developed de novo AF during hospitalization due to ACS were older (75±12 vs 66±14 years, p<0.001) and with higher prevalence of cardiovascular risk factors and cardiovascular disease. AF was more often in patients with ST elevation ACS (53.4%). During hospitalization, AF patients were more often medicated with aspirin, glycoprotein inhibitor, heparin, fondaparinux and vitamin K antagonists. No difference was found regarding P2Y12 inhibitors. AF patients presented more often obstructive coronary disease (normal coronaries 5.4 vs 8.5%, p<0.001) so they were more often submitted to PCI (79.5 vs 70.9%, p<0.001). AF patients presented with higher rates of adverse in-hospital events as re-infarction, heart failure, shock, ventricular arrhythmias, cardiac arrest, stroke, major bleeding and death (p<0.001). At discharge, AF patients were less prescribed with aspirin or ticagrelor, but the rate of clopidogrel prescription was higher, such as vitamin K antagonists or any of the new anticoagulants. In the AF group, 21.5% patients were discharged with TAT and 30.3% with DAT. Concerning patients discharged with TAT, 1-year follow-up revealed no significant differences in mortality (p=0.578), re-admission for cardiovascular causes (p=0.301) and total re-admission rates (p=0.291). Patients discharged with DAT had similar mortality (p=0.623) and re-admission for cardiovascular causes rates (p=0.138), but significant differences were identified regarding total re-admissions (p=0.024).
Conclusions
In patients with ACS and de novo AF, a low percentage of patients was discharged with oral anticoagulation (51.8%). In those whose anticoagulation was initiated, DAT was the preferred strategy. 1-year outcomes were not different between the antithrombotic strategy, except for all cause re-admission.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- I Almeida
- Hospital N.S. Rosario, Barreiro, Portugal
| | - H Santos
- Hospital N.S. Rosario, Barreiro, Portugal
| | - M Santos
- Hospital N.S. Rosario, Barreiro, Portugal
| | - H Miranda
- Hospital N.S. Rosario, Barreiro, Portugal
| | - J Chin
- Hospital N.S. Rosario, Barreiro, Portugal
| | - C Sa
- Hospital N.S. Rosario, Barreiro, Portugal
| | - S Almeida
- Hospital N.S. Rosario, Barreiro, Portugal
| | - C Sousa
- Hospital N.S. Rosario, Barreiro, Portugal
| | - L Almeida
- Hospital N.S. Rosario, Barreiro, Portugal
| | | |
Collapse
|
2
|
Borges-Rosa J, Oliveira-Santos M, Simoes M, Carvalho P, Ibanez-Sanchez G, Fernandez-Llatas C, Costa M, Monteiro S, Goncalves L. The role of process mining tools in STEMI networks: where should we build a new primary PCI centre? Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
In ST-segment elevation myocardial infarction (STEMI), time delay between symptom onset and treatment is critical to improve outcome. The expected transport delay between patient location and percutaneous coronary intervention (PCI) centre is paramount for choosing the adequate reperfusion therapy. The “Centre” region of Portugal has heterogeneity in PCI assess due to geographical reasons.
Purpose
We aimed to explore time delays between regions using process mining (PM) tools.
Methods
We retrospectively assessed the Portuguese Registry of Acute Coronary Syndromes for patients with STEMI from October 2010 to September 2019, collecting information on geographical area of symptom onset, reperfusion option, and in-hospital mortality. We used a PM toolkit (PM4H – PMApp Version) to build two models (one national and one regional) that represent the flow of patients in a healthcare system, enhancing time differences between groups. One-way analysis of variance was employed for the global comparison of study variables between groups and post hoc analysis with Bonferroni correction was used for multiple comparisons.
Results
Overall, 8956 patients (75% male, 48% from 51 to 70 years) were included in the national model (Fig. 1A), in which primary PCI was the treatment of choice (73%), with the median time between admission and primary PCI <120 minutes in every region; “Lisboa” and “Centro” had the longest delays, (orange arrows). Fibrinolysis was performed in 4.5%, with a median time delay <1 hour in every region. In-hospital mortality was 5%, significantly higher for those without reperfusion therapy compared to PCI and fibrinolysis (10% vs. 4% vs. 4%, P<0.001). In the regional model (Fig. 1B) corresponding to the “Centre” region of Portugal divided by districts (n=773, 74% male, 47% from 51 to 70 years), only 61% had primary PCI, with “Guarda” (05:04) and “Castelo Branco” (06:50) showing significant longer delays between diagnosis and reperfusion treatment (orange and red arrows, respectively) than “Coimbra” (01:19) (green arrow); only 15% of patients from “Castelo Branco” had primary PCI. Fibrinolysis was chosen in 10% of patients, mostly in “Castelo Branco” (53%), followed by “Guarda” (30%), with a median time delay of 39 and 48 minutes, respectively. Regarding mortality, PCI and fibrinolysis groups had similar death rates while those patients without reperfusion had higher mortality (5% vs. 3% vs. 13%, P=0.001).
Conclusion
Process mining tools help to understand referencing networks visually, easily highlighting inefficiencies and potential needs for improvement. The “Centre” region of Portugal has lower rates and longer delay to primary PCI partially due to the geographical reasons, with worse outcomes in remote regions. The implementation of a new PCI centre in one of these districts, is critical to offer timely first-line treatment to their population.
Funding Acknowledgement
Type of funding sources: None. Figure 1
Collapse
Affiliation(s)
| | | | - M Simoes
- Coimbra Institute for Biomedical Imaging and Translational Research, Coimbra, Portugal
| | - P Carvalho
- Centre for Informatics and Systems of the University of Coimbra, Coimbra, Portugal
| | - G Ibanez-Sanchez
- Polytechnic University of Valencia, SABIEN-ITACA, Valencia, Spain
| | | | - M Costa
- University Hospitals of Coimbra, Coimbra, Portugal
| | - S Monteiro
- University Hospitals of Coimbra, Coimbra, Portugal
| | - L Goncalves
- University Hospitals of Coimbra, Coimbra, Portugal
| | | |
Collapse
|
3
|
Soares F, Santos L, Sa FM, Carvalho R, Saraiva F, Pernencar S, Antunes A, Correia J, Morais J. P5570Complete revascularization does not reduce the incidence of new-onset heart failure during admission for acute coronary syndrome in patients with multivessel disease. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- F Soares
- Hospital Santo Andre, Cardiology, Leiria, Portugal
| | - L Santos
- Hospital Santo Andre, Cardiology, Leiria, Portugal
| | - F M Sa
- Hospital Santo Andre, Cardiology, Leiria, Portugal
| | - R Carvalho
- Hospital Santo Andre, Cardiology, Leiria, Portugal
| | - F Saraiva
- Hospital Santo Andre, Cardiology, Leiria, Portugal
| | - S Pernencar
- Hospital Santo Andre, Cardiology, Leiria, Portugal
| | - A Antunes
- Hospital Santo Andre, Cardiology, Leiria, Portugal
| | - J Correia
- Hospital Santo Andre, Cardiology, Leiria, Portugal
| | - J Morais
- Hospital Santo Andre, Cardiology, Leiria, Portugal
| | | |
Collapse
|